Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype release_fw6ordzbj5aunhr7n45eqmq3km

by Mirna Swayden, Juan Iovanna, Philippe Soubeyran

Published in Heliyon by Elsevier BV.

2018   Volume 4, Issue 12, e01055

Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest forms of cancer. A major reason for this situation is the fact that these tumors are already resistant or become rapidly resistant to all conventional therapies. Like any transformation process, initiation and development of PDCA are driven by a well known panel of genetic alterations, few of them are shared with most cancers, but many mutations are specific to PDAC and are partially responsible for the great inter-tumor heterogeneity. Importantly, this knowledge has been inefficient in predicting response to anticancer therapy, or in establishing diagnosis and prognosis. Hence, the pre-existing or rapidly acquired resistance of pancreatic cancer cells to therapeutic drugs rely on other parameters and features developed by the cells and/or the micro-environment, that are independent of their genetic profiles. This review sheds light on all major phenotypic, non genetic, alterations known to play important roles in PDAC cells resistance to treatments and therapeutic escape.
In text/plain format

Archived Files and Locations

application/pdf  670.5 kB
file_6peixofynjhszkbap5irxb5vne
europepmc.org (repository)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2018-12-17
Language   en ?
Container Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  2405-8440
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 285449af-eec7-418f-842b-47cb62eb953b
API URL: JSON